Vor Biopharma (VOR) Competitors

$14.33 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$14.41 +0.08 (+0.56%)

As of 05/22/2026 07:51 PM Eastern

VOR vs. DNLI, RCUS, BEAM, TNGX, and GMTX

Should you buy Vor Biopharma stock or one of its competitors? MarketBeat compares Vor Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vor Biopharma include Denali Therapeutics (DNLI), Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Denali Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 0.5% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Denali Therapeutics currently has a consensus price target of $34.25, indicating a potential upside of 83.74%. Vor Biopharma has a consensus price target of $42.25, indicating a potential upside of 194.84%. Given Vor Biopharma's higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vor Biopharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Vor Biopharma	N/A	N/A	N/A

Vor Biopharma has lower revenue, but higher earnings than Denali Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	8.95	-$512.54M	-$2.88	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Vor Biopharma had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Vor Biopharma and 2 mentions for Denali Therapeutics. Vor Biopharma's average media sentiment score of 0.64 beat Denali Therapeutics' score of -0.33 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Denali Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Vor Biopharma has lower revenue, but higher earnings than Arcus Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	11.95	-$353M	-$3.18	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Vor Biopharma's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Vor Biopharma	N/A	N/A	N/A

Arcus Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arcus Biosciences currently has a consensus target price of $33.89, indicating a potential upside of 44.36%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 194.84%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Vor Biopharma had 8 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Vor Biopharma and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.87 beat Vor Biopharma's score of 0.64 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Arcus Biosciences on 9 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Beam Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Vor Biopharma has lower revenue, but higher earnings than Beam Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.09	-$79.99M	-$0.68	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Vor Biopharma had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 9 mentions for Vor Biopharma and 7 mentions for Beam Therapeutics. Vor Biopharma's average media sentiment score of 0.64 beat Beam Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 0.5% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vor Biopharma has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Vor Biopharma's return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Vor Biopharma	N/A	N/A	N/A

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 63.52%. Vor Biopharma has a consensus price target of $42.25, indicating a potential upside of 194.84%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Vor Biopharma beats Beam Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Tango Therapeutics presently has a consensus target price of $32.27, suggesting a potential upside of 59.45%. Vor Biopharma has a consensus target price of $42.25, suggesting a potential upside of 194.84%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Tango Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Vor Biopharma has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Vor Biopharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Vor Biopharma	N/A	N/A	N/A

Vor Biopharma has lower revenue, but higher earnings than Tango Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	46.93	-$101.59M	-$0.83	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Vor Biopharma had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Vor Biopharma and 2 mentions for Tango Therapeutics. Vor Biopharma's average media sentiment score of 0.64 beat Tango Therapeutics' score of -0.40 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vor Biopharma beats Tango Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 194.84%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, Vor Biopharma had 8 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Vor Biopharma and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat Vor Biopharma's score of 0.64 indicating that Gemini Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vor Biopharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Gemini Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$776.49M	$431.67M	$4.25B	$12.32B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	N/A	N/A	21.96	25.66
Price / Sales	N/A	332.23	125.30	111.99
Price / Cash	N/A	N/A	55.68	56.67
Price / Book	N/A	3.25	34.85	7.14
Net Income	N/A	-$81.71M	$112.32M	$335.98M
7 Day Performance	1.42%	0.41%	2.55%	3.56%
1 Month Performance	3.77%	2.02%	3.54%	2.54%
1 Year Performance	N/A	N/A	15.79%	35.05%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.6559 of 5 stars	$14.33 flat	$42.25 +194.8%	N/A	$776.49M	N/A	N/A	140	Gap Up
DNLI Denali Therapeutics	3.078 of 5 stars	$18.64 -3.4%	$34.25 +83.7%	+38.9%	$2.96B	$330.53M	N/A	430	Analyst Forecast
RCUS Arcus Biosciences	3.6523 of 5 stars	$23.48 -1.7%	$33.89 +44.4%	+159.5%	$2.95B	$247M	N/A	500
BEAM Beam Therapeutics	3.2674 of 5 stars	$28.64 +3.5%	$46.83 +63.5%	+70.2%	$2.95B	$139.74M	N/A	510	Gap Down
TNGX Tango Therapeutics	2.4414 of 5 stars	$20.24 -6.4%	$32.27 +59.5%	+1,000.0%	$2.93B	$62.38M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. DNLI, RCUS, BEAM, TNGX, and GMTX

How does Vor Biopharma compare to Denali Therapeutics?

Summary

How does Vor Biopharma compare to Arcus Biosciences?

Summary

How does Vor Biopharma compare to Beam Therapeutics?

Summary

How does Vor Biopharma compare to Tango Therapeutics?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. DNLI, RCUS, BEAM, TNGX, and GMTX

How does Vor Biopharma compare to Denali Therapeutics?

Which has more volatility & risk, DNLI or VOR?

Do insiders and institutionals believe in DNLI or VOR?

Do analysts recommend DNLI or VOR?

Is DNLI or VOR more profitable?

Which has preferable earnings & valuation, DNLI or VOR?

Does the media favor DNLI or VOR?

Summary

How does Vor Biopharma compare to Arcus Biosciences?

Which has stronger valuation & earnings, RCUS or VOR?

Is RCUS or VOR more profitable?

Which has more volatility and risk, RCUS or VOR?

Do institutionals & insiders believe in RCUS or VOR?

Do analysts recommend RCUS or VOR?

Does the media favor RCUS or VOR?

Summary

How does Vor Biopharma compare to Beam Therapeutics?

Which has more risk & volatility, BEAM or VOR?

Which has better earnings and valuation, BEAM or VOR?

Does the media favor BEAM or VOR?

Do institutionals and insiders believe in BEAM or VOR?

Is BEAM or VOR more profitable?

Do analysts recommend BEAM or VOR?

Summary

How does Vor Biopharma compare to Tango Therapeutics?

Do analysts recommend TNGX or VOR?

Which has more volatility & risk, TNGX or VOR?

Is TNGX or VOR more profitable?

Which has preferable earnings and valuation, TNGX or VOR?

Does the media prefer TNGX or VOR?

Do institutionals and insiders have more ownership in TNGX or VOR?

Summary

How does Vor Biopharma compare to Gemini Therapeutics?

Do analysts recommend GMTX or VOR?

Which has more volatility and risk, GMTX or VOR?

Does the media prefer GMTX or VOR?

Which has better earnings and valuation, GMTX or VOR?

Do institutionals & insiders believe in GMTX or VOR?

Is GMTX or VOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools